Company intelligence / Profile preview

ProMed Management

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

ProMed Management is a healthcare-focused investment management company that operates a family of funds specializing in the life sciences, biotechnology, and medical device sectors. Founded in 1996 by David Musket and Barry Kurokawa, the firm acts as a crossover investor, participating in both private venture rounds and public equity financings for emerging healthcare companies. ProMed Management is well-known in the biotech industry for its strategic investments in companies such as Capricor Therapeutics, Repros Therapeutics, and Conor MedSystems. The firm provides capital and strategic guidance to its portfolio companies, often holding significant equity positions and representation on boards of directors.

Industry: Investors

Beyond the preview

Go deeper on ProMed Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProMed Management.

Explore the full profile